Exploring the level of agreement among different drug-drug interaction checkers : a comparative study on direct oral anticoagulants

BACKGROUND: Direct oral anticoagulants (DOACs) may be involved in drug-drug interactions (DDIs) potentially increasing the risk of adverse drug reactions. This study aimed to evaluate the level of agreement among interaction checkers (ICs) and DOACs' summary of product characteristics (SPCs), in listing DDIs and in attributing DDIs' severity.

RESEARCH DESIGN AND METHODS: The level of agreement among five ICs (i.e. INTERCheck WEB, Micromedex, Lexicomp, Epocrates, and drugs.com) in identifying potential DDIs and in attributing severity categories was evaluated using Gwet's AC1 on all five ICs and by comparing groups of four- and two-pair sets of ICs.

RESULTS: A total of 486 potentially interacting drugs with dabigatran, 556 for apixaban, 444 for edoxaban, and 561 for rivaroxaban were reported. The level of agreement among the ICs in identifying potential DDIs was poor (range: 0.12-0.16). Similarly, it was low in 4 and 2 sets analyses. The level of agreement among the ICs in classifying the severity of potential DDIs was poor (range: 0.32-0.34), also in 4 and 2 sets analyses.

CONCLUSIONS: The heterogeneity among different ICs and SPCs underscores the need to standardize DDI datasets and to conduct real-world studies to generate evidence regarding the frequency and clinical relevance of potential DOAC-related DDIs.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:20

Enthalten in:

Expert opinion on drug metabolism & toxicology - 20(2024), 3 vom: 31. März, Seite 157-164

Sprache:

Englisch

Beteiligte Personen:

Carollo, Massimo [VerfasserIn]
Crisafulli, Salvatore [VerfasserIn]
Ciccimarra, Francesco [VerfasserIn]
Andò, Giuseppe [VerfasserIn]
Diemberger, Igor [VerfasserIn]
Trifirò, Gianluca [VerfasserIn]

Links:

Volltext

Themen:

9NDF7JZ4M3
Anticoagulants
Dabigatran
Direct-acting oral anticoagulants
Drug–drug interactions
Gwet’s AC1
I0VM4M70GC
Interaction checkers
Journal Article
Rivaroxaban
Summary of product characteristics

Anmerkungen:

Date Completed 26.03.2024

Date Revised 26.03.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1080/17425255.2024.2322134

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM368761118